Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
- Conditions
- Oropharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 663
- Registration Number
- NCT06771674
- Locations
- 🇺🇸
Cardinal Health, Dublin, Ohio, United States
A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
- Conditions
- Oropharyngeal Squamous Cell Carcinoma Recurrent
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 450
- Registration Number
- NCT06513884
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People with HIV on Suppressive ART
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- Biological: HB-502 and HB-501 alternating 2-vector therapy Dose Level 1Biological: HB-502 and HB-501 alternating 2-vector therapy Dose Level 2Other: Placebo
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT06430905
- Locations
- 🇺🇸
Orlando Immunology Center (OIC), Orlando, Florida, United States
🇺🇸The Hope Clinic at Emory University, Decatur, Georgia, United States
🇺🇸Brigham and Women´s Hospital, Boston, Massachusetts, United States
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer Metastatic
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT05553639
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), San Marcos, California, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
- Conditions
- HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
- Interventions
- Drug: HB-201 IV
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Hookipa Biotech GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT04630353
- Locations
- 🇺🇸
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Prev
- 1
- 2
- Next